Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets

AbbVie is partnering with Disco Pharmaceuticals, a preclinical cancer biotech, to build out its antibody-drug conjugate and T cell engager programs. The Cologne, Germany-headquartered biotech will receive $40 million upfront and up to $2.5 billion ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 19 November →